Global Anticoccidial Drugs Market Size to Reach $268.1 Million at a CAGR of 4.3% by 2032
Vantage Market Research expects the Anticoccidial Drugs Market to reach USD 268.1 Million by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032.
The Global Anticoccidial Drugs Market size reached USD 184.3 Million in 2023. Vantage Market Research expects the market to reach USD 268.1 Million by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032.
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The market for Anticoccidial Drugs is booming due to various factors such as strategic acquisitions, technological advancements, regulatory support, and the introduction of innovative products. This active environment demonstrates the industry's dedication to tackling changing challenges in animal health and responding to consumer preferences and regulatory trends.
Request Sample Report of Anticoccidial Drugs Market @ https://www.vantagemarketresearch.com/anticoccidial-drugs-market-2423/request-sample
Top Companies in Global Anticoccidial Drugs Market
- Bayer AG (Germany)
- Bioproperties Pty Ltd. (Australia)
- Boehringer Ingelheim International GmbH (Germany)
- Ceva Sante Animale (France)
- Cronus Pharma LLC (U.S.)
- Elanco Animal Health Inc. (U.S.)
- Huvepharma EOOD (Bulgaria)
- Impextraco NV (Belgium)
- Kemin Industries Inc. (U.S.)
- LABORATORIOS HIPRA SA (Spain)
- Merck and Co. Inc. (U.S.)
- Novartis AG (Switzerland)
- Phibro Animal Health Corp. (U.S.)
As a division of Oil-Dri® Corporation of America, Amlan® International is a firm committed to animal nutrition and health. In June 2023, the company announced that it had fully purchased Agromex Importaciones, S.A. de C.V., solidifying its position in the Mexican market. This acquisition was a crucial step forward in Amlan's plans to expand and achieve its goals.
Oil-Dri obtained a large portion of Agromex Importaciones, allowing them to become a part of Mexico's growing animal health industry. Amlan then decided to acquire the remaining shares of Agromex, showing their dedication to making the most of Agromex's capabilities. By fully owning Agromex, Amlan plans to expand the area and take advantage of the significant market provided by Mexico's poultry industry, which handles around 46 million broilers weekly.
Amlan's objective of offering cutting-edge feed additives, such as Varium®, NeoPrime®, Phylox®, Calibrin® -Z, and Calibrin® -A, is well supported by this strategic acquisition. These products are carefully formulated to improve the health of the intestines, boost animal performance, and resolve specific issues that arise in animal production.
Continuous advancements in drug discovery and veterinary medicine are driving the growth of the Anticoccidial Drugs Market. By embracing advanced technologies like genomics, proteomics, and high-throughput screening methods, the industry has transformed the process of identifying new compounds with improved effectiveness and fewer side effects.
The development of new-generation Anticoccidial Drugs, such as toltrazuril and diclazuril, is a clear example of the technological advancements that have been made. These drugs are more potent and safer compared to older versions, which has played a significant role in expanding the market. By utilizing advanced technologies, scientists can create drugs that address the increasing need for effectiveness and safety in animal health.
Companies that invest in research and development activities show their dedication to innovation. This focus helps develop new and advanced drugs to address the market's changing demands. For example, Boehringer Ingelheim's upcoming launch of Vaxxilive Cocci 3 in 2024 is a vaccine for poultry coccidiosis that serves as a biological substitute for drugs given in animal feed. This highlights the industry's commitment to advancing preventive measures while minimizing any negative impact on animal health.
Regulatory support is critical in helping the Anticoccidial Drugs Market grow faster. The US Department of Agriculture's Center for Veterinary Biologics has sent a letter to ZIVO Bioscience, Inc., indicating that they have the right to evaluate the company's novel immune-modulating biologic intended to treat coccidiosis in broiler chickens. This recognition from the regulatory agency gives companies a clear direction for bringing new and innovative solutions to the market. When regulatory bodies acknowledge and approve new biological products, it gives companies more confidence and makes it easier for them to introduce innovative products. This recognition also guarantees that these new products meet the required safety and effectiveness standards, which in turn helps the market grow.
Buy Now Our Anticoccidial Drugs Industry Report @ https://www.vantagemarketresearch.com/buy-now/anticoccidial-drugs-market-2423/0
In the market for Anticoccidial Drugs, collaborations and partnerships are essential because they foster the development of novel and creative solutions and make a wider range of possible products. Companies are coming together to combine their resources and knowledge, resulting in the development of products that specifically target challenges in animal health. A prime example is the partnership between Boehringer Ingelheim and Phileo by Lesaffre. They worked together to create and distribute a new anticoccidial product for poultry. This collaboration expanded the range of available products and demonstrated the industry's joint efforts in sharing resources and expertise to improve animal health.
Companies in the Anticoccidial Drugs Market use different strategies, like acquiring or merging with other companies, to increase their presence in various areas and access new markets. These strategic efforts benefit companies as they help them grow their size, improve their market position, and keep up with competitors on a global scale. For instance, Zoetis, a significant player in the animal health industry, acquired Abaxis, a company specializing in veterinary diagnostics. This acquisition aimed to empower Zoetis's position in the animal health market, highlighting the importance of strategic investments in achieving dominance in the industry.
Companies in the anticoccidial drug industry concentrate on marketing and promotional initiatives to grow their market share and raise consumer awareness of their products. They are using online advertising and social media campaigns and are participating in industry conferences and exhibitions. These efforts help educate people about the advantages of their products and establish their brand. In 2020, Huvepharma expanded its distribution network in Brazil by partnering with veterinary product distributors. This expansion helped them reach more customers and showed dedication to serving a more extensive customer base.
In January 2024, Boehringer Ingelheim's introduction of Vaxxilive Cocci 3 demonstrates the industry's dedication to innovation. This vaccine for chicken coccidiosis represents advancements in preventative methods with no impact on birds' health and provides a biological substitute for drugs found in animal feed. Anticoccidial Drugs Market has a promising future owing to a combination of new product introductions, technological improvements, regulatory body backing, and strategic acquisitions. The industry is focused on tackling challenges, meeting regulations, and offering efficient and sustainable solutions. As a result, it is expected to experience steady growth in the changing field of animal health.
Read Our Latest Press Release: Cutter Stapler Market - In-depth Analysis
Contact us
Eric Kunz
6218 Georgia Avenue NW Ste 1 - 564
Washington DC 20011-5125
United States Tel: +1 202 380 9727
Email: [email protected]
Website: Vantage Market Research